Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paul Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS), Universite Pierre Et Marie Curie (Paris 6), Icm (Institut Du Cerveau Et De La Moelle éPinièRe)
InventorsDaniel Dunia, Marion Szelechowski, Alexandre Betourne, Stephane Hunot
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.
Claims13
A fusion protein comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less;
- and
- II) at least one heterologous polypeptide fused to the polypeptide.
A nucleic acid sequence encoding a fusion protein comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less;
- and
- II) at least one heterologous polypeptide.
A vector comprising a nucleic acid sequence encoding a fusion protein comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less;
- and
- II) at least one heterologous polypeptide.
A prokaryotic or eukaryotic host cell genetically transformed with at least one nucleic acid molecule encoding a fusion protein comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less;
- and
- II) at least one heterologous polypeptide;
- or
- a vector comprising the nucleic acid.
A pharmaceutical composition comprising
- a pharmaceutically acceptable carrier;
- and
- a fusion protein comprising
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less;
- and
- II) at least one heterologous polypeptide.
A recombinant polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1, wherein the polypeptide consists of 86 amino acids or less.
A vector comprising a nucleic acid sequence encoding
- I) a polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less.
A prokaryotic or eukaryotic host cell genetically transformed with at least one nucleic acid molecule encoding
- I) a recombinant polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less.
A pharmaceutical composition comprising
- a pharmaceutically acceptable carrier;
- and
- I) a recombinant polypeptide comprising
- i) an amino acid sequence ranging from glycine at position 59 to alanine at position 85 in an amino acid sequence SEQ ID NO:1 or,
- ii) an amino acid sequence having at least 90% identity with the amino acid sequence ranging from glycine at position 59 to alanine at position 85 in the amino acid sequence SEQ ID NO:1,
- wherein the polypeptide consists of 86 amino acids or less.
Dependencies are inferred from the claim text.